Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J3373
10 MG
Medicare payment limit per unit (Q4 2026): $0.032
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 600 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 600 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| DME supplier services | 600 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.032per 10 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.032 | 10 MG | 20% | −3.0% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.033 | 10 MG | 20% | +10.0% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.030 | 10 MG | 20% | −3.2% | — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.031 | 10 MG | 20% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 70860-0104-10 | Vancomycin HClAthenex Pharmaceutical Division, LLC | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 70860-0105-20 | Vancomycin HClAthenex Pharmaceutical Division, LLC | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 00338-0122-04 | Vancomycin HClBaxter Healthcare Corporation | 250 × 4 | 125 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00338-0124-04 | Vancomycin HClBaxter Healthcare Corporation | 300 × 4 | 150 | 600 | $19.20 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00338-3551-48 | Vancomycin HClBaxter Healthcare Corporation | 100 × 1 | 50 | 600 | $19.20 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00338-3552-48 | Vancomycin HClBaxter Healthcare Corporation | 200 × 1 | 100 | 600 | $19.20 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00338-3580-48 | Vancomycin HClBaxter Healthcare Corporation | 150 × 1 | 75 | 450 | $14.40 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00338-3581-01 | Vancomycin HClBaxter Healthcare Corporation | 100 × 1 | 50 | 600 | $19.20 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00338-3582-01 | Vancomycin HClBaxter Healthcare Corporation | 150 × 1 | 75 | 450 | $14.40 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00338-3583-01 | Vancomycin HClBaxter Healthcare Corporation | 200 × 1 | 100 | 600 | $19.20 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 68001-0407-75 | Vancomycin HClBluePoint Laboratories | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 72572-0029-10 | Vancomycin HClCivica, Inc. | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2026 – Q4 2026 | ListedVancomycin Hydrochloride |
| 72572-0105-01 | Vancomycin HClCivica, Inc. | 1 × 1 | 500 | 500 | $16.00 | ASP | Q2 2026 – Q4 2026 | ListedVancomycin Hydrochloride |
| 72572-0207-01 | Vancomycin HClCivica, Inc. | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q2 2026 – Q4 2026 | ListedVancomycin Hydrochloride |
| 72572-0801-02 | Vancomycin HClCivica, Inc. | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 72572-0803-01 | Vancomycin HClCivica, Inc. | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 72572-0805-01 | Vancomycin HClCivica, Inc. | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 63323-0203-20 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 10 | 75 | 750 | $24.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0203-26 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 10 | 75 | 750 | $24.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0221-10 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 25 | 50 | 1,250 | $40.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0221-16 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 25 | 50 | 1,250 | $40.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0284-20 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0284-26 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0295-61 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0295-66 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0314-61 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 63323-0314-66 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 68462-0955-51 | Vancomycin HClGlenmark Pharmaceuticals Inc., USA | 1 × 10 | 50 | 500 | $16.00 | ASP | Q4 2026 | ListedVancomycin Hydrochloride |
| 68462-0956-11 | Vancomycin HClGlenmark Pharmaceuticals Inc., USA | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q4 2026 | ListedVancomycin Hydrochloride |
| 00404-9965-99 | Vancomycin HClHenry Schein Inc. | 1 × 1 | 50 | 50 | $1.60 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00143-9355-10 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 10 | 75 | 750 | $24.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00143-9357-10 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00143-9358-01 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00143-9359-01 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 71288-0022-11 | Vancomycin HClMeitheal Pharmaceuticals Inc. | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 71288-0023-21 | Vancomycin HClMeitheal Pharmaceuticals Inc. | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 71288-0024-21 | Vancomycin HClMeitheal Pharmaceuticals Inc. | 1 × 10 | 75 | 750 | $24.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 71288-0025-75 | Vancomycin HClMeitheal Pharmaceuticals Inc. | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 71288-0026-75 | Vancomycin HClMeitheal Pharmaceuticals Inc. | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 67457-0339-50 | Vancomycin HClMylan Institutional LLC | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 67457-0340-01 | Vancomycin HClMylan Institutional LLC | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 67457-0341-05 | Vancomycin HClMylan Institutional LLC | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 67457-0342-10 | Vancomycin HClMylan Institutional LLC | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 16714-0309-10 | Vancomycin HClNorthstar RxLLC | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 00409-1319-01 | Vancomycin HClPfizer Inc | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00409-3515-01 | Vancomycin HClPfizer Inc | 1 × 10 | 150 | 1,500 | $48.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00409-4332-01 | Vancomycin HClPfizer Inc | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00409-5017-01 | Vancomycin HClPfizer Inc | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 00409-6509-01 | Vancomycin HClPfizer Inc | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00409-6509-49 | Vancomycin HClPfizer Inc | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00409-6531-01 | Vancomycin HClPfizer Inc | 1 × 10 | 75 | 750 | $24.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 00409-6531-02 | Vancomycin HClPfizer Inc | 1 × 10 | 75 | 750 | $24.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00409-6533-21 | Vancomycin HClPfizer Inc | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00409-6533-31 | Vancomycin HClPfizer Inc | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 00409-6534-01 | Vancomycin HClPfizer Inc | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 00409-6535-01 | Vancomycin HClPfizer Inc | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 25021-0150-10 | Vancomycin HClSagent Pharmaceuticals | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 25021-0151-20 | Vancomycin HClSagent Pharmaceuticals | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 25021-0157-99 | Vancomycin HClSagent Pharmaceuticals | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin |
| 25021-0158-99 | Vancomycin HClSagent Pharmaceuticals | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin |
| 70436-0020-82 | Vancomycin HClSlate Run Pharmaceuticals | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 70436-0021-82 | Vancomycin HClSlate Run Pharmaceuticals | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 70436-0022-82 | Vancomycin HClSlate Run Pharmaceuticals | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 70436-0023-82 | Vancomycin HClSlate Run Pharmaceuticals | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 70594-0045-02 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | Not found |
| 70594-0046-02 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 70594-0047-01 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 1 | 500 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 70594-0048-01 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 1 | 1,000 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | Excluded listingVancomycin Hydrochloride |
| 70594-0122-02 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 10 | 50 | 500 | $16.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
| 70594-0123-02 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 10 | 100 | 1,000 | $32.00 | ASP | Q3 2025 – Q4 2026 | ListedVancomycin Hydrochloride |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 72611-0765-10 | Vancomycin HClAlmaject, Inc. | 1 × 10 | 100 | 1,000 | ASP | Q3 2025 – Q4 2025Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q3 2025 | Added to HCPCS | A — Added | Added date Jul 1, 2025 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| Prescribing Information |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| +3.3% |
| — |
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.030 | 10 MG | 20% | −3.2% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.031 | 10 MG | 20% | — | Added July 2025 |
|---|
| 55150-0471-10 | Vancomycin HClEugia US LLC | 1 × 10 | 125 | 1,250 | ASP | Q3 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
|---|
| 55150-0472-10 | Vancomycin HClEugia US LLC | 1 × 10 | 150 | 1,500 | ASP | Q3 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
|---|
| 00143-9152-10 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 10 | 125 | 1,250 | ASP | Q3 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
|---|
| 00143-9153-10 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 10 | 150 | 1,500 | ASP | Q3 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
|---|
| 16714-0247-10 | Vancomycin HClNorthstar RxLLC | 1 × 10 | 50 | 500 | ASP | Q3 2025 – Q1 2026Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
|---|